A recent report from Stat News indicates a decrease in federal lobbying efforts by cannabis industry operators. Notably, Curaleaf, a significant player in the industry, reduced its lobbying spending in Washington, D.C., by almost 40% during the first half of the year compared to its peak spending in 2019. Furthermore, both Columbia Care and Pax Labs took more drastic measures by eliminating their lobbying teams.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…